Cargando…
Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial
SIMPLE SUMMARY: Most patients with glioblastoma, the most frequent primary brain tumor in adults, develop resistance to standard first-line treatment combining temozolomide and radiotherapy. Signaling through the hepatocyte growth factor receptor (c-MET) and the midkine (ALK ligand) promotes gliomag...
Autores principales: | Martínez-García, María, Velasco, Guillermo, Pineda, Estela, Gil-Gil, Miguel, Alameda, Francesc, Capellades, Jaume, Martín-Soberón, Mari Cruz, López-Valero, Israel, Tovar Ambel, Elena, Foro, Palmira, Taus, Álvaro, Arumi, Montserrat, Hernández-Laín, Aurelio, Sepúlveda-Sánchez, Juan Manuel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139576/ https://www.ncbi.nlm.nih.gov/pubmed/35625997 http://dx.doi.org/10.3390/cancers14102393 |
Ejemplares similares
-
SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)
por: Segura, Pedro Pérez, et al.
Publicado: (2023) -
SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)
por: Martínez-García, María, et al.
Publicado: (2022) -
Nezahualcóyotl, Acolmiztli, 1402-1472
por: Alva Ixtlilxóchitl, Fernando de, 1402-1472
Publicado: (1972) -
MYL-1402O: A Bevacizumab Biosimilar
por: Lee, Arnold
Publicado: (2021) -
Correction to: MYL-1402O: A Bevacizumab Biosimilar
por: Lee, Arnold
Publicado: (2022)